2009-12-04 7:00 AM - 11:00 AM
New Developments in Immunotherapy for Hematologic Malignancies
This program is sponsored by the University of Medicine and Dentistry of New Jersey and supported by Millennium Pharmaceuticals, Inc., and the Leukemia and Lymphoma Society.
| Location: |
Ernest N. Morial Convention Center, Room 393-396 |
| Speakers: |
Ronald Levy, MD, Stanford University, Stanford, CA
Oliver W. Press, MD, PhD, Fred Hutchinson Cancer Center, Seattle, WA
Carl H. June, MD, Abramson Family Cancer Research Institute at the University of Pennsylvania, Philadelphia, PA
Hyam I. Levitsky, MD, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
Michel Sadelain, MD, PhD, Memorial Sloan-Kettering Cancer Center, New York, NY |
This symposium will cover topics in the area of immunotherapy, including studies of radio-labeled monoclonal antibodies for hematologic malignancies, immunological checkpoint modulation for lymphoma, adoptive T-cell therapy, and genetically enhanced T-lymphocyte studies. The goal of the program will be to provide hematologists, oncologists, and other health-care professionals with a better understanding of immunotherapy, as well as to improve their ability to select appropriate therapies in this promising area of research and treatment.
For more information, contact Jeanne Fryar, Robert Michael Educational Institute.
Phone: 856-672-3354
Fax: 856-546-7030
back to top
Navigating the Therapeutic Pathways for AML and MDS
This program is sponsored by the Medical College of Wisconsin and supported by the National Marrow Donor Program.
| Location: |
Ernest N. Morial Convention Center, Room 293-296 |
| Speakers: |
Willis Navarro, MD, National Marrow Donor Program, Minneapolis, MN
Steven Devine, MD, Ohio State University, Columbus, OH
Fred Appelbaum, MD, Fred Hutchinson Cancer Research Center, Seattle, WA
Daniel Weisdorf, MD, University of Minnesota, Minneapolis, MN
Dennis Confer, MD, National Marrow Donor Program, Minneapolis, MN |
The optimal treatment algorithm for patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) is highly variable and complex and must be individualized. Some patients are best treated without transplantation, while it is the only potentially curative option for others. This program will explore the current state-of-the-art AML and MDS treatments with a view to the role of risk stratification in treatment decision making. The outcomes for various therapeutic options, such as chemotherapy and autologous and allogeneic transplantation, will be reviewed. Special clinical issues in AML and MDS will also be discussed, such as refractory disease and the role of novel molecular diagnostics.
For more information, contact Renee Ryan, National Marrow Donor Program.
Phone: 612-884-8430
Fax: 612-627-5877
back to top